TapewireFind a company

person · Reporting owner

Calvin Sandra

Disclosed activity across 1 company

Tapewire entity
52348
SEC CIK
0001882909

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Travere Therapeutics, Inc.TVTX · Entity 1562SVP, CHIEF ACCOUNTING OFFICERSeptember 15, 2026September 18, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Travere Therapeutics, Inc.

Report date September 15, 2026 · Filed September 18, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect42,353 Ending reported balance After 2026-09-15 transaction · row 6
6 source rows · reconciled sequence

Row 1 · 2026-09-15 · Exercise / conversion · Acquired 2,500 · Balance 44,853

Row 2 · 2026-09-15 · Exercise / conversion · Acquired 1,250 · Balance 46,103

Row 3 · 2026-09-15 · Exercise / conversion · Acquired 1,625 · Balance 47,728

Row 4 · 2026-09-15 · Sale · Disposed 4,275 · Balance 43,453

F1: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

F2: The weighted average sale price for the transaction reported was $62.135, and the range of prices were between $61.53 and $62.51. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

Row 5 · 2026-09-15 · Sale · Disposed 800 · Balance 42,653

F1: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

F3: The weighted average sale price for the transaction reported was $62.8481, and the range of prices were between $62.62 and $63.19. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

Row 6 · 2026-09-15 · Sale · Disposed 300 · Balance 42,353

F1: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

F4: The weighted average sale price for the transaction reported was $63.6633, and the range of prices were between $63.64 and $63.71. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

Employee stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.50 · Expires 2032-01-31Direct0 Reported balance After 2026-09-15 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2026-09-15 · Exercise / conversion · Disposed 2,500 · Balance 0

F5: The stock option is fully vested and exercisable.

Employee stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.40 · Expires 2033-01-31Direct3,750 Reported balance After 2026-09-15 transaction · row 8 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 8 · 2026-09-15 · Exercise / conversion · Disposed 1,250 · Balance 3,750

F6: One-fourth of the shares subject to the stock option vested and became exercisable on the first anniversary of January 31, 2023, and the remaining shares vest in 36 equal monthly installments thereafter.

Employee stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.46 · Expires 2035-01-31Direct17,875 Reported balance After 2026-09-15 transaction · row 9 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 9 · 2026-09-15 · Exercise / conversion · Disposed 1,625 · Balance 17,875

F7: One-fourth of the shares subject to the stock option vested and become exercisable on the first anniversary of January 31, 2025, and the remaining shares vest in 36 equal monthly installments thereafter.

Filing footnotes · ownership attribution and instrument terms

F1: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

F2: The weighted average sale price for the transaction reported was $62.135, and the range of prices were between $61.53 and $62.51. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

F3: The weighted average sale price for the transaction reported was $62.8481, and the range of prices were between $62.62 and $63.19. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

F4: The weighted average sale price for the transaction reported was $63.6633, and the range of prices were between $63.64 and $63.71. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

F5: The stock option is fully vested and exercisable.

F6: One-fourth of the shares subject to the stock option vested and became exercisable on the first anniversary of January 31, 2023, and the remaining shares vest in 36 equal monthly installments thereafter.

F7: One-fourth of the shares subject to the stock option vested and become exercisable on the first anniversary of January 31, 2025, and the remaining shares vest in 36 equal monthly installments thereafter.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
December 26, 2024 Filed Dec 28, 2024 00:47 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 SaleCommon Stock 15,000 $17.22 $258,277.50
Disclosure

SEC source: 0001415889-24-030210 · form4-12282024_121201.xml · nonDerivative · entry 2

Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 54,927

F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, adopted by the Reporting Person on September 9, 2024.

F2 · price: The weighted average sale price for the transaction reported was $17.21856, and the range of prices were between $16.985 and $17.545. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

Read SEC document
December 26, 2024 Filed Dec 28, 2024 00:47 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 Exercise / conversionCommon Stock 15,000 $12.67 $190,050.00
Disclosure

SEC source: 0001415889-24-030210 · form4-12282024_121201.xml · nonDerivative · entry 1

Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 69,927

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
November 25, 2024 Filed Nov 26, 2024 02:00 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 Exercise / conversionEmployee stock option (right to buy) · Derivative 15,000 $0.00 Strike: $12.67 $0.00
Disclosure

SEC source: 0001415889-24-027672 · form4-11262024_021145.xml · derivative · entry 3

Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2025-01-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The stock option is fully vested and exercisable.

Read SEC document
November 25, 2024 Filed Nov 26, 2024 02:00 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 SaleCommon Stock 12,090 $18.30 $221,257.88
Disclosure

SEC source: 0001415889-24-027672 · form4-11262024_021145.xml · nonDerivative · entry 2

Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,927

F1 · shares: Represents the number of shares required to be sold by the Reporting Person in order to cover the tax withholding obligation and payment of the exercise price in connection with the partial exercise of a stock option granted to the Reporting Person on January 2, 2015 with an upcoming expiration date of January 2, 2025.

F2 · price: The weighted average sale price for the transaction reported was $18.3009, and the range of prices were between $18.27 and $18.37. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

Read SEC document
November 25, 2024 Filed Nov 26, 2024 02:00 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 Exercise / conversionCommon Stock 15,000 $12.67 $190,050.00
Disclosure

SEC source: 0001415889-24-027672 · form4-11262024_021145.xml · nonDerivative · entry 1

Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,017

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 01, 2024 Filed Feb 2, 2024 21:05 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 SaleCommon Stock 2,820 $8.53 $24,057.98
Disclosure

SEC source: 0001415889-24-002279 · form4-02022024_040202.xml · nonDerivative · entry 3

Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,017

F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

F3 · price: The weighted average sale price for the reported transaction was $8.5312, and the range of prices were between $8.5309 and $8.5315. Upon request by the SEC staff, the Issuer or any securityholder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Read SEC document
January 31, 2024 Filed Feb 2, 2024 21:05 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 GrantEmployee stock option (right to buy) · Derivative 25,000 $0.00 Strike: $8.93 $0.00
Disclosure

SEC source: 0001415889-24-002279 · form4-02022024_040202.xml · derivative · entry 4

Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2034-01-30

F4 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.

Read SEC document
January 31, 2024 Filed Feb 2, 2024 21:05 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 GrantCommon Stock 1,000 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-002279 · form4-02022024_040202.xml · nonDerivative · entry 2

Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,837

F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.

Read SEC document
January 31, 2024 Filed Feb 2, 2024 21:05 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 GrantCommon Stock 12,500 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-002279 · form4-02022024_040202.xml · nonDerivative · entry 1

Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,837

F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.

Read SEC document
January 23, 2024 Filed Jan 25, 2024 21:10 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 SaleCommon Stock 910 $9.07 $8,252.24
Disclosure

SEC source: 0001415889-24-001796 · form4-01252024_040102.xml · nonDerivative · entry 1

Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,337

F1 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

Read SEC document
May 11, 2023 Filed May 12, 2023 20:06 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 SaleCommon Stock 122 $16.12 $1,966.64
Disclosure

SEC source: 0001209191-23-028993 · doc4.xml · nonDerivative · entry 2

Calvin Sandra · CIK 0001882909 · SVP, Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 42,247

F2 · kind: The sales reported in this Form 4 were made pursuant to a written plan adopted by the Reporting Person on September 14, 2022 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

Read SEC document
May 10, 2023 Filed May 12, 2023 20:06 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 SaleCommon Stock 436 $16.59 $7,233.24
Disclosure

SEC source: 0001209191-23-028993 · doc4.xml · nonDerivative · entry 1

Calvin Sandra · CIK 0001882909 · SVP, Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 42,369

F1 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

Read SEC document
February 02, 2023 Filed Feb 2, 2023 23:53 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 SaleCommon Stock 360 $22.42 $8,071.20
Disclosure

SEC source: 0001209191-23-006413 · doc4.xml · nonDerivative · entry 3

Calvin Sandra · CIK 0001882909 · SVP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,805

F3 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

Read SEC document
February 01, 2023 Filed Feb 2, 2023 23:53 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 SaleCommon Stock 1,671 $21.75 $36,347.59
Disclosure

SEC source: 0001209191-23-006413 · doc4.xml · nonDerivative · entry 2

Calvin Sandra · CIK 0001882909 · SVP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,165

F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

Read SEC document
January 31, 2023 Filed Feb 2, 2023 23:53 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 GrantEmployee stock option (right to buy) · Derivative 20,000 $0.00 Strike: $22.40 $0.00
Disclosure

SEC source: 0001209191-23-006413 · doc4.xml · derivative · entry 4

Calvin Sandra · CIK 0001882909 · SVP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2033-01-30

F4 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.

Read SEC document
January 31, 2023 Filed Feb 2, 2023 23:53 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 GrantCommon Stock 10,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-006413 · doc4.xml · nonDerivative · entry 1

Calvin Sandra · CIK 0001882909 · SVP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,836

F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.

Read SEC document
January 25, 2023 Filed Jan 26, 2023 21:05 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 SaleCommon Stock 192 $21.63 $4,152.96
Disclosure

SEC source: 0001209191-23-005037 · doc4.xml · nonDerivative · entry 2

Calvin Sandra · CIK 0001882909 · SVP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,836

F2 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

Read SEC document
January 24, 2023 Filed Jan 26, 2023 21:05 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 SaleCommon Stock 905 $21.90 $19,823.48
Disclosure

SEC source: 0001209191-23-005037 · doc4.xml · nonDerivative · entry 1

Calvin Sandra · CIK 0001882909 · SVP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,028

F1 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

Read SEC document
September 13, 2022 Filed Sep 15, 2022 20:05 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 SaleCommon Stock 349 $28.00 $9,772.00
Disclosure

SEC source: 0001209191-22-050038 · doc4.xml · nonDerivative · entry 1

Calvin Sandra · CIK 0001882909 · SVP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,933

F1 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

F2 · balance_after: Includes 549 shares of the Issuer's common stock acquired by the reporting person on May 31, 2022 pursuant to an employee stock purchase program.

Read SEC document
May 11, 2022 Filed May 13, 2022 00:44 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 SaleCommon Stock 445 $21.92 $9,755.96
Disclosure

SEC source: 0001209191-22-028706 · doc4.xml · nonDerivative · entry 2

Calvin Sandra · CIK 0001882909 · SVP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,733

F1 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

Read SEC document
May 10, 2022 Filed May 13, 2022 00:44 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 SaleCommon Stock 436 $21.51 $9,378.36
Disclosure

SEC source: 0001209191-22-028706 · doc4.xml · nonDerivative · entry 1

Calvin Sandra · CIK 0001882909 · SVP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,178

F1 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

Read SEC document
January 31, 2022 Filed Feb 2, 2022 21:22 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 GrantEmployee stock option (right to buy) · Derivative 17,500 $0.00 Strike: $27.50 $0.00
Disclosure

SEC source: 0001209191-22-006372 · doc4.xml · derivative · entry 3

Calvin Sandra · CIK 0001882909 · VP, Corp Controller and CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,500

Underlying: Common Stock · 17,500 shares

Expires 2032-01-30

F3 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.

Read SEC document
January 31, 2022 Filed Feb 2, 2022 21:22 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 SaleCommon Stock 798 $26.51 $21,151.71
Disclosure

SEC source: 0001209191-22-006372 · doc4.xml · nonDerivative · entry 2

Calvin Sandra · CIK 0001882909 · VP, Corp Controller and CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,614

F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

Read SEC document
January 31, 2022 Filed Feb 2, 2022 21:22 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 GrantCommon Stock 8,750 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-006372 · doc4.xml · nonDerivative · entry 1

Calvin Sandra · CIK 0001882909 · VP, Corp Controller and CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,412

F1 · kind: Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan that are scheduled to vest over four years.

Read SEC document
January 24, 2022 Filed Jan 26, 2022 21:38 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 SaleCommon Stock 934 $24.58 $22,954.64
Disclosure

SEC source: 0001209191-22-005084 · doc4.xml · nonDerivative · entry 1

Calvin Sandra · CIK 0001882909 · VP, Corp Controller and CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,662

F1 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

F2 · balance_after: Includes 842 shares of the Issuer's common stock acquired by the reporting person on November 30, 2021 pursuant to an employee stock purchase program.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.